Physician profile
Donald Cochran
NPI 1295801983
$1,969.73
in general payments reported to CMS, 2019-2025
13 companies · $881 in 2025
The $881 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2021: $370 · 2023: $149 · 2024: $426 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $610.47 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $519.44 | 2025 | Tryptyr, Voyager Dslt, Hydrus Microstent |
| Allergan, INC. | $117.87 | 2021 | |
| Aerie Pharmaceuticals, INC. | $112.07 | 2019 | |
| Astellas Pharma US INC | $105.76 | 2024 | Izervay |
| Dompe US, INC. | $101.36 | 2024 | Oxervate |
| Coopervision INC. | $99.44 | 2021 | |
| Amgen INC. | $93.67 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $63.71 | 2021 | |
| Glaukos Corporation | $51.28 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.50 | 2021 | |
| Abb Con-Cise Optical Group LLC | $32.02 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $25.14 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.